Northwest Biotherapeutics Stock May Fade On Misleading Press Release

On July 9, 2007, tiny Northwest Biotherapeutics (NWBO.OB) issued a press release entitled “World’s First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland.” The release stated that the company received an “authorization for use” from the Swiss authorities and that “DCVax-Brain is the first commercially available therapeutic vaccine for such cancers. The Company intends to begin making the product available to patients in Q3 2007.”

Investors and the press understood the approval to be a marketing approval, and shares more than doubled on enormous volume. Northwest’s President and CEO Dr. Alton Boynton fostered this misunderstanding, stating in the July 9 release:

We are delighted to be the first company to reach the market with a personalized therapeutic vaccine for brain cancers, which carry a very bleak prognosis for patients today. We look forward to providing DCVax-Brain at leading medical centers and hospitals in Switzerland.

A week later, the company issued another press release explaining that the authorization it received was really just for import/export purposes, and was conditional even for those limited purposes. The company now says that the Swiss government has not yet reviewed DCVax for neither safety nor efficacy. Northwest tried to blame the confusion on “certain media reports,” but any fair assessment has to fault the company’s misleading July 9 press release.

My take: DCVax may hold a lot of promise, but it will be years before it is truly commercialized in Switzerland or anywhere else. I think the stock is likely to fade back to $2, retracing 100% of the recent rally, as investors wait for more news. Still, I’m keeping the company on my watch list. This fall or winter, after the company does begin making the product available to patients, we will likely see another positive press release and another spike upwards.

NWBO.OB 1-year chart

Disclosure: No position.

Comments

[hpski:]

Well well.....here we are more than a month after NWBO's misleading press release, and no Wall St. "ambulance chaser" has, at least publicly, announced a class action shareholders suit? IMO this is truly ironic - gluttonous attorneys were on DNDN's valuation carcass like Marinol inebriated buzzards, with much, much less, grist for the mill vs this situation. But none of this surprises me - for many people in biopharm, it's about the money - patients are viewed as part of the foundation they're building for future empires and stock option awards.

2007 Aug 12 05:56 PM

[bradpiit:]

The real estate business in Mexico and Central America is different from the way that it is conducted in the United States.

Some similarities include a variety of legal formalities (with professionals such as real estate agents generally employed to assist the buyer); taxes need to be paid (but typically less than those in U.S.); legal paperwork will ensure title; and a neutral party such as a title company will handle documentation and monies in order to make the exchange between the parties smooth. Increasingly, U.S. title companies are doing work for U.S. buyers in Mexico and Central America.

real estate

May 31 11:29 PM

[bradpiit:]

real estate

May 31 11:29 PM